Total trials
471
Active
211
Phase 3
31
Total enrollment
4,281,995
Pipeline matrix
Showing 40 of 206 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| BiTE | — | — | — | — | — | 2 | |
| Oxycodone Hydrochloride | — | — | — | — | — | 1 | |
| Evolocumab | — | — | — | — | — | 1 | |
| Standard Lipid-Lowering Therapy | — | — | — | — | — | 1 | |
| Abrupt Discontinuation of Propranolol | — | — | — | — | — | 1 | |
| Gradual Tapering of Propranolol | — | — | — | — | — | 1 | |
| Proton Pump Inhibitors | — | — | — | — | — | 1 | |
| No Proton Pump Inhibitors | — | — | — | — | — | 1 | |
| Sufentanil Citrate | — | — | — | — | 2 | ||
| Toripalimab | — | — | — | 4 | |||
| Serplulimab | — | — | — | — | 2 | ||
| Sirolimus | — | — | — | 6 | |||
| Disitamab Vedotin | — | — | — | — | 2 | ||
| GnP | — | — | — | — | — | 1 | |
| patients were assigned to receive TNT or iTNT management | — | — | — | — | — | 1 | |
| Capox chemotherapy | — | — | — | — | — | 1 | |
| desiccated thyroid extract | — | — | — | — | — | 1 | |
| Anti-PD-1 antibody drug named Serplulimab | — | — | — | — | — | 1 | |
| Chemotherapy | — | — | — | — | — | 1 | |
| Mecobalamin | — | — | — | — | — | 1 | |
| Topical application of Periplaneta americana-derived Meilian Fuxin Solution | — | — | — | — | — | 1 | |
| SBRT+PD-1 Inhibitor + Chemotherapy | — | — | — | — | — | 1 | |
| PD-1 Inhibitor + Chemotherapy | — | — | — | — | — | 1 | |
| Temozolomide | — | — | — | — | — | 1 | |
| Gemcitabine + Cisplatin（GC）+Toripalimab | — | — | — | — | — | 1 | |
| Propranolol | — | — | — | — | 6 | ||
| Camrelizumab | — | — | — | — | 8 | ||
| Tislelizumab | — | — | — | — | 11 | ||
| Afatinib | — | — | — | — | 8 | ||
| Apatinib | — | — | — | — | — | 5 | |
| Sintilimab | — | — | — | — | 4 | ||
| Bevacizumab | — | — | — | — | — | 3 | |
| Palbociclib | — | — | — | — | 3 | ||
| PD-1 inhibitor | — | — | — | — | — | 2 | |
| Lysogenic HSV virus. | — | — | — | — | 2 | ||
| Tagitanlimab | — | — | — | — | — | 2 | |
| Lenvatinib | — | — | — | — | — | 2 | |
| Irinotecan Liposome | — | — | — | — | — | 2 | |
| JDB153 | — | — | — | — | — | 2 | |
| Engineered mitochondrial vaccine | — | — | — | — | 2 |
166 more active programs hidden
Next readouts
- 2023-04-10
- 2023-12-01
- 2023-12-31
- 2024-04-24
- 2024-06-01
- 2024-10-01
- 2024-10-31
- 2024-11-01
- 2024-12
- 2024-12-01
Top conditions
- Colorectal Cancer13
- Head and Neck Squamous Cell Carcinoma11
- Portal Hypertension10
- Rectal Cancer9
- Immunotherapy8
- Gastric Cancer8
- Liver Cancer8
- Head and Neck Cancer7
Frequently asked questions about West China Hospital
- How many clinical trials does West China Hospital have on ClinicalTrials.gov?
- West China Hospital is listed as the lead sponsor on 471 clinical trials in ClinicalTrials.gov, 211 of which are currently active (recruiting, enrolling, or ongoing).
- How many of West China Hospital's trials are in Phase 3?
- 31 of West China Hospital's trials are in Phase 3, spread across 206 active drug programs.
- What therapeutic areas does West China Hospital focus on?
- West China Hospital's most-studied conditions on ClinicalTrials.gov are Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, Portal Hypertension, Rectal Cancer, Immunotherapy.
- When are West China Hospital's next clinical trial readouts?
- West China Hospital has 10 upcoming primary-completion readouts tracked here; the soonest is “Radiotherapy Versus Radiotherapy Combined With Temozolomide in High-risk Low-grade Gliomas After Surgery”, expected around 2023-04-10.